VT-101

AXP000061.1 · Oncolytic virus

Platform
adenovirus
Sponsor
The Affiliated Hospital of Xuzhou Medical University

Names

NameTypeSource
VT-101 ambiguouspreferred name, codecurator, ctgov

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus (serotype not reported)
Replication
conditionally replicating
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07905677Phase 1 Study of VT-101 in Advanced Ovarian CancerRecruitingPhase 12026-10-262029-10-2322Epithelial Ovarian Cancer; Ovarian Cancer
NCT06632964A Clinical Trial Aimed at Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder CancerUnknownPhase 12024-09-182025-09-0116Non-muscle Invasive Bladder Cancer

Recent changes

SeenTrialChangeDetailTitle
2026-11-12NCT07905677new trialPhase 1 Study of VT-101 in Advanced Ovarian Cancer

Clinical papers

PubMedTitleJournalYearLinked by
PMID 39035212Cancer incidence and mortality in China, 2016.Journal of the National Cancer Center2022cited by trial NCT06632964
PMID 33924556Oncolytic Virotherapy for Cancer: Clinical Experience.Biomedicines2021cited by trial NCT06632964
PMID 32615118Cancer registration in China and its role in cancer prevention and control.The Lancet. Oncology2020cited by trial NCT06632964
PMID 28755959An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.Urologic oncology2018cited by trial NCT06632964
PMID 28981385Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2018cited by trial NCT06632964
PMID 28712033Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.Cancer immunology, immunotherapy : CII2017cited by trial NCT06632964
PMID 28886381Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.Cell2017cited by trial NCT06632964
PMID 26014293Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2015cited by trial NCT06632964
PMID 23088985A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer.The Journal of urology2012cited by trial NCT06632964

Notes

Recombinant oncolytic adenovirus injection, NCT06632964. Construct not described in the registration.

How to cite

VT-101 (AXP000061.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000061.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.